Learn how a leading pharma brand drove immediate patient action and improved access to injectable migraine prevention medication.

Overcoming access and affordability barriers is critical for patients relying on injectable migraine prevention medications. This success story reveals how a targeted outreach program led to a 63% copay card usage at first fill and other significant results: 

• 3%+ absolute incremental lift with 48-hour reinforcement message.
• 49% of patients continued use with refills/renewals.

Download the full case study to discover the strategy behind this success.